Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nephrology | 7 | 2024 | 162 | 2.090 |
Why?
|
| Peritoneal Dialysis | 6 | 2024 | 133 | 1.690 |
Why?
|
| Renal Dialysis | 9 | 2022 | 951 | 1.530 |
Why?
|
| Kidney Failure, Chronic | 7 | 2024 | 934 | 1.460 |
Why?
|
| Critical Illness | 8 | 2021 | 630 | 1.350 |
Why?
|
| Renal Replacement Therapy | 4 | 2021 | 172 | 1.060 |
Why?
|
| Renal Insufficiency, Chronic | 8 | 2024 | 853 | 1.020 |
Why?
|
| Acute Kidney Injury | 3 | 2021 | 705 | 0.680 |
Why?
|
| Intensive Care Units | 8 | 2021 | 526 | 0.650 |
Why?
|
| Reimbursement Mechanisms | 1 | 2020 | 36 | 0.610 |
Why?
|
| Blood Coagulation Disorders | 1 | 2021 | 102 | 0.610 |
Why?
|
| Uromodulin | 1 | 2019 | 12 | 0.590 |
Why?
|
| Pyelonephritis | 1 | 2019 | 26 | 0.580 |
Why?
|
| Specialization | 1 | 2019 | 75 | 0.580 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 689 | 0.580 |
Why?
|
| Health Policy | 2 | 2020 | 234 | 0.570 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 240 | 0.550 |
Why?
|
| Anticoagulants | 2 | 2021 | 605 | 0.500 |
Why?
|
| Ambulatory Care | 1 | 2020 | 401 | 0.480 |
Why?
|
| Hospital Mortality | 8 | 2021 | 1064 | 0.430 |
Why?
|
| Respiratory Insufficiency | 2 | 2021 | 247 | 0.420 |
Why?
|
| Prone Position | 2 | 2021 | 30 | 0.380 |
Why?
|
| Physicians | 1 | 2019 | 635 | 0.380 |
Why?
|
| Patient Positioning | 2 | 2021 | 48 | 0.370 |
Why?
|
| Caregivers | 4 | 2024 | 598 | 0.370 |
Why?
|
| Delphi Technique | 5 | 2024 | 283 | 0.370 |
Why?
|
| Kidney Diseases | 2 | 2021 | 477 | 0.350 |
Why?
|
| United States | 14 | 2021 | 12072 | 0.350 |
Why?
|
| Pandemics | 4 | 2021 | 1118 | 0.350 |
Why?
|
| Respiration, Artificial | 2 | 2021 | 501 | 0.300 |
Why?
|
| Hypoxia | 1 | 2021 | 247 | 0.300 |
Why?
|
| Renal Insufficiency | 2 | 2022 | 259 | 0.280 |
Why?
|
| Humans | 33 | 2024 | 131163 | 0.280 |
Why?
|
| History, 20th Century | 2 | 2020 | 365 | 0.270 |
Why?
|
| Insurance, Health | 1 | 2017 | 146 | 0.250 |
Why?
|
| Insurance Coverage | 1 | 2017 | 120 | 0.240 |
Why?
|
| Aged | 15 | 2024 | 21025 | 0.240 |
Why?
|
| Medicare | 1 | 2018 | 442 | 0.220 |
Why?
|
| Survival Rate | 4 | 2024 | 2114 | 0.210 |
Why?
|
| Middle Aged | 15 | 2024 | 28601 | 0.210 |
Why?
|
| Focus Groups | 2 | 2020 | 239 | 0.180 |
Why?
|
| Male | 20 | 2024 | 64957 | 0.180 |
Why?
|
| Nephritis, Interstitial | 1 | 2022 | 41 | 0.180 |
Why?
|
| Mortality | 2 | 2021 | 264 | 0.180 |
Why?
|
| Kidney Glomerulus | 1 | 2021 | 81 | 0.170 |
Why?
|
| Female | 20 | 2024 | 70963 | 0.170 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 38 | 0.170 |
Why?
|
| Acid-Base Equilibrium | 1 | 2021 | 60 | 0.160 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2020 | 11 | 0.160 |
Why?
|
| China | 1 | 2021 | 278 | 0.160 |
Why?
|
| Patient Outcome Assessment | 1 | 2020 | 89 | 0.150 |
Why?
|
| Cohort Studies | 6 | 2021 | 5063 | 0.150 |
Why?
|
| Fatigue | 1 | 2020 | 191 | 0.150 |
Why?
|
| Language | 1 | 2021 | 219 | 0.150 |
Why?
|
| Health Personnel | 1 | 2024 | 541 | 0.150 |
Why?
|
| Patients | 1 | 2020 | 122 | 0.150 |
Why?
|
| Disease Progression | 3 | 2020 | 2200 | 0.140 |
Why?
|
| Hypertension | 1 | 2017 | 1356 | 0.140 |
Why?
|
| History, 19th Century | 1 | 2019 | 109 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2020 | 263 | 0.140 |
Why?
|
| Terminology as Topic | 1 | 2020 | 226 | 0.140 |
Why?
|
| Quality of Life | 3 | 2021 | 2082 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 222 | 0.140 |
Why?
|
| Organ Transplantation | 1 | 2020 | 175 | 0.140 |
Why?
|
| Bacteriuria | 1 | 2019 | 80 | 0.130 |
Why?
|
| Venous Thromboembolism | 1 | 2021 | 195 | 0.130 |
Why?
|
| Forecasting | 1 | 2019 | 351 | 0.130 |
Why?
|
| Hospitalization | 3 | 2021 | 1950 | 0.130 |
Why?
|
| Pain | 1 | 2020 | 450 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 275 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2021 | 487 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 570 | 0.120 |
Why?
|
| Heart Arrest | 1 | 2020 | 356 | 0.120 |
Why?
|
| Acute Disease | 1 | 2019 | 1153 | 0.120 |
Why?
|
| Prognosis | 3 | 2020 | 4886 | 0.120 |
Why?
|
| Comorbidity | 3 | 2021 | 1595 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 339 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 351 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2019 | 1246 | 0.110 |
Why?
|
| Critical Care | 1 | 2020 | 686 | 0.110 |
Why?
|
| Registries | 1 | 2021 | 1634 | 0.100 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 682 | 0.100 |
Why?
|
| Adult | 10 | 2024 | 31282 | 0.100 |
Why?
|
| Biomarkers | 2 | 2021 | 3385 | 0.100 |
Why?
|
| Blood Pressure | 2 | 2020 | 1345 | 0.100 |
Why?
|
| Research Design | 2 | 2021 | 716 | 0.090 |
Why?
|
| Blood Pressure Determination | 1 | 2020 | 118 | 0.070 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 209 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 1129 | 0.070 |
Why?
|
| Policy Making | 1 | 2018 | 63 | 0.070 |
Why?
|
| Clinical Studies as Topic | 1 | 2017 | 11 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2021 | 1483 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 2121 | 0.060 |
Why?
|
| Program Development | 1 | 2018 | 179 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2018 | 447 | 0.060 |
Why?
|
| Young Adult | 4 | 2021 | 10103 | 0.060 |
Why?
|
| Risk Factors | 4 | 2020 | 11074 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 6797 | 0.060 |
Why?
|
| Medicaid | 1 | 2017 | 268 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2018 | 407 | 0.050 |
Why?
|
| Agrochemicals | 1 | 2022 | 13 | 0.050 |
Why?
|
| Paraquat | 1 | 2022 | 14 | 0.050 |
Why?
|
| Cations | 1 | 2022 | 38 | 0.050 |
Why?
|
| Adolescent | 4 | 2021 | 20987 | 0.040 |
Why?
|
| Visual Analog Scale | 1 | 2020 | 8 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2021 | 12936 | 0.040 |
Why?
|
| Thrombophilia | 1 | 2021 | 41 | 0.040 |
Why?
|
| Organ Dysfunction Scores | 1 | 2021 | 53 | 0.040 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2021 | 40 | 0.040 |
Why?
|
| Early Medical Intervention | 1 | 2021 | 32 | 0.040 |
Why?
|
| Frustration | 1 | 2020 | 5 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2021 | 184 | 0.040 |
Why?
|
| Administrative Personnel | 1 | 2020 | 27 | 0.040 |
Why?
|
| Nephrologists | 1 | 2020 | 19 | 0.040 |
Why?
|
| Stakeholder Participation | 1 | 2020 | 35 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 135 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 237 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 173 | 0.040 |
Why?
|
| Comprehension | 1 | 2020 | 81 | 0.040 |
Why?
|
| United Kingdom | 1 | 2020 | 267 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 256 | 0.040 |
Why?
|
| Fear | 1 | 2020 | 190 | 0.040 |
Why?
|
| Self-Management | 1 | 2020 | 120 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 333 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 386 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 1410 | 0.030 |
Why?
|
| Psychometrics | 1 | 2020 | 678 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1490 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2020 | 17753 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1797 | 0.030 |
Why?
|
| Communication | 1 | 2020 | 543 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 726 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 4066 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2825 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2904 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3829 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 4738 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 3061 | 0.020 |
Why?
|
| Incidence | 1 | 2020 | 3360 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5196 | 0.020 |
Why?
|
| Mice | 1 | 2022 | 18301 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 33912 | 0.010 |
Why?
|